Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

首页> 外文期刊>AIDS & hepatitis digest >Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

【24h】

Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

机译：Elbasvir / Grazoprevir在丙型肝炎病毒感染和补偿肝硬化患者中的安全性和有效性：综合分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In this study, published in Gastroenterology, 2017, Jacobson and colleagues analyzed data from 6 clinical trials, and found that rates of SVR12 ranged from 89% to 100% in patients with HCV genotype 1, 4, or 6 infections and compensated cirrhosis treated with elbasvir/grazoprevir, with or without ribavirin. The addition of ribavirin to a 12-week regimen of elbasvir/grazoprevir had little effect on proportion of treatment-naive or treatment- experienced patients who achieved an SVR12. However, virologic failure did not occur in any treatment-experienced patients when the duration of elbasvir/grazoprevir and ribavirin therapy was extended to 16 or 18 weeks.

机译：None

著录项

来源
《AIDS & hepatitis digest》 |2017年第2期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis [J] . Estefania Berge, Ana Arencibia, Elena Otón, 肝癌研究（英文版） . 2017,第009期
2. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis [J] . Jacobson Ira M., Lawitz Eric, Kwo Paul Y., Gastroenterology . 2017,第6期

机译：Elbasvir / Grazoprevir在丙型肝炎病毒感染和补偿肝硬化患者中的安全性和有效性：综合分析
3. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial [J] . Lawitz Eric, Gane Edward, Pearlman Brian, The Lancet . 2015,第9973期

机译：接受或未接受利巴韦林的格拉佐普韦（MK-5172）和依巴斯韦（MK-8742）治疗丙型肝炎病毒基因型1感染的12周和18周治疗对以前未经治疗的肝硬化患者和既往有或没有治疗无效的患者的疗效和安全性无肝硬化（C-WORTHY）：一项随机，开放标签的2期临床试验
4. Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection: An Integrated Analysis of Data from 11 Phase 2/3 Trials [J] . Lai Wei, Kumada Hiromitsu, Perumalswami Ponni V., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Elbasvir / Grazoprevir在亚洲参与者中丙型肝炎病毒基因型1和4感染的安全性和有效性：来自11期2/3试验的数据的综合分析
5. Phylogenetic Analysis the 5'-Noncoding Sequences of the Hepatitis C Virus Detected from the Patient with HCV Infection [C] . Nguyen Thai Son, Pham Hung Van The third international conference on the development of biomedical engineering in Vietnam . 2010

机译：从HCV感染患者中检测到的丙型肝炎病毒5'-非编码序列的系统发育分析
6. A serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among inmates entering the California correctional system. [D] . Ruiz, Juan Domingo. 1997

机译：对进入加利福尼亚教养系统的囚犯进行的人类免疫缺陷病毒，乙型肝炎病毒和丙型肝炎病毒感染的血清调查。
7. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis [O] . Yinan Yao, Ming Yue, Jie Wang, 2017

机译：Grazoprevir和Elbasvir在基因1型丙型肝炎病毒感染患者中的作用：全面的疗效和安全性分析
8. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis [O] . Yinan Yao, Ming Yue, Jie Wang, 2017

机译：Grazoprevir和Elbasvir在基因型1丙型肝炎病毒感染中的患者：综合疗效和安全分析
9. Recommendations for Postexposure Interventions to Prevent Infection with Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Similar Mass-Casualty Events-United States, 2008: Recommendations of the Centers for Disease Control (CDC). Morbidity and Mortality Weekly Report, Recommendation and Reports, Vol.57, No. RR-6 [R] . 2008

机译：关于暴露后干预以防止乙型肝炎病毒，丙型肝炎病毒或人类免疫缺陷病毒感染的建议，以及在爆炸和类似的大规模伤亡事件中受伤人员的破伤风 - 美国，2008年：疾病控制中心（CDC）的建议。发病率和死亡率每周报告，建议和报告，第57卷，第RR-6号

Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

摘要

著录项

相似文献

相关主题

期刊订阅